Acadia Expects Broad Nuplazid Reimbursement; Pricing Soon

Acadia Pharmaceuticals Inc. has not yet priced its newly approved Parkinson's disease psychosis (PDP) drug Nuplazid (pimavanserin), but anticipates it will be covered by a vast majority of payers. The PDP approval also sets the stage for expanding Nuplazid's use into other indications, including Alzheimer's disease psychosis and agitation.

While Acadia Pharmaceuticals Inc. disappointed investors and analysts during a May 2 conference call by not disclosing the price of the firm's newly approved Parkinson's disease psychosis (PDP) drug Nuplazid (pimavanserin), the company insisted the medicine, nonetheless, is likely to be covered by the "vast majority" of payers.

Analysts, however, anticipated Acadia to reveal Nuplazid's price as soon as May 5, when the firm holds its quarterly earnings...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip